News & Updates
Filter by Specialty:
Resmetirom demos potential in NASH
Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.
Resmetirom demos potential in NASH
18 Jul 2022
Electroacupuncture helps fight insomnia in patients with depression
For patients with depression who struggle to fall asleep, electroacupuncture can help with getting a better night’s sleep, with sustained effects, as shown in a study.
Electroacupuncture helps fight insomnia in patients with depression
18 Jul 2022
Nonexercise estimated cardiorespiratory fitness tied to reduced hypertension risk
Adults with good cardiorespiratory fitness, estimated by a nonexercise algorithm, have a lower risk of developing hypertension, suggests a study.
Nonexercise estimated cardiorespiratory fitness tied to reduced hypertension risk
18 Jul 2022
Weekly dose-dense CT does not confer survival benefit for ovarian cancer patients
In the final analysis of the phase III ICON8* study, a weekly dose-dense chemotherapy (CT) regimen comprising paclitaxel and carboplatin did not improve survival outcomes in women with epithelial ovarian cancer** compared with the standard first-line (1L) paclitaxel-carboplatin regimen given once every 3 weeks (Q3W).
Weekly dose-dense CT does not confer survival benefit for ovarian cancer patients
18 Jul 2022
Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.
